These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19433677)

  • 1. Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it?
    Glaspy J; Ribas A; Chmielowski B
    J Clin Oncol; 2009 Jun; 27(18):2896-7. PubMed ID: 19433677
    [No Abstract]   [Full Text] [Related]  

  • 2. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
    Moschos SJ; Kirkwood JM; Konstantinopoulos PA
    J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 4. Malignant melanoma (non-metastatic).
    Crosby T; Mason M; Savage P
    Clin Evid; 2003 Dec; (10):1897-909. PubMed ID: 15555184
    [No Abstract]   [Full Text] [Related]  

  • 5. Malignant melanoma (non-metastatic).
    Crosby T; Mason M; Savage P
    Clin Evid; 2004 Dec; (12):2321-35. PubMed ID: 15865791
    [No Abstract]   [Full Text] [Related]  

  • 6. Malignant melanoma (non-metastatic).
    Crosby T; Mason M; Savage P
    Clin Evid; 2005 Dec; (14):2058-72. PubMed ID: 16620482
    [No Abstract]   [Full Text] [Related]  

  • 7. Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma.
    Mohr P; Hauschild A; Trefzer U; Weichenthal M
    J Clin Oncol; 2009 Aug; 27(24):e70; author reply e71. PubMed ID: 19620476
    [No Abstract]   [Full Text] [Related]  

  • 8. How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?
    Tarhini AA; Kirkwood JM
    J Clin Oncol; 2012 Nov; 30(31):3773-6. PubMed ID: 23008298
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant interferon therapy for melanoma.
    Hancock B; Wheatley K; Ives N; Gore M
    J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
    [No Abstract]   [Full Text] [Related]  

  • 10. [After removal of a malignant melanoma. Enhancing the immune system!].
    MMW Fortschr Med; 1999 Nov; 141(44):66. PubMed ID: 10912153
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy, cytokines, and biochemotherapy for melanoma.
    Eton O
    Cancer Chemother Biol Response Modif; 2005; 22():739-48. PubMed ID: 16110637
    [No Abstract]   [Full Text] [Related]  

  • 12. [Underutilization of anticancer agents--an example].
    Strannegård O; Thorén FB
    Lakartidningen; 2010 Dec 8-14; 107(49):3150; discussion 3150-1. PubMed ID: 21280349
    [No Abstract]   [Full Text] [Related]  

  • 13. [Sarcoidosis, myasthenia gravis and anterior ischaemic optic neuropathy: severe side effects of adjuvant interferon-alpha-therapy in malignant melanoma?].
    Kreutzer K; Bonnekoh B; Franke I; Ulrich J; Gollnick H
    J Dtsch Dermatol Ges; 2004 Aug; 2(8):689-94. PubMed ID: 16279234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypertriglyceridemia induced by interferon].
    Iborra C; Martinet C; Prigent F
    Ann Dermatol Venereol; 1996; 123(10):677. PubMed ID: 9615133
    [No Abstract]   [Full Text] [Related]  

  • 15. Measurement of matrix metalloproteinases in serum of patients with melanoma: snarled in technical pitfalls.
    Zucker S; Cao J
    Clin Cancer Res; 2005 Jul; 11(14):5069-70. PubMed ID: 16033818
    [No Abstract]   [Full Text] [Related]  

  • 16. Systemic sclerosis induced by interferon-alfa treatment of melanoma.
    Silva JL; Faria DS; Teixeira F; Afonso MC; Peixoto D
    Acta Reumatol Port; 2017; 42(3):263-264. PubMed ID: 28482357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interferon-alpha can improve the prognosis in high-risk melanoma. Combination of surgery, cytostatics and natural IFN-alpha doubled the survival rate].
    Strannegärd O; Thorén FB; Lundgren E
    Lakartidningen; 2008 Feb 6-12; 105(6):358-61. PubMed ID: 18380352
    [No Abstract]   [Full Text] [Related]  

  • 18. How to manage melanoma in a psoriatic patient.
    Papadavid E; Psyrri A; Pectasides D; Katoulis A; Balamoti E; Dalamaga M; Stavrianeas N
    Dermatology; 2008; 216(3):277-8. PubMed ID: 18196939
    [No Abstract]   [Full Text] [Related]  

  • 19. How melanoma is treated in real life.
    Dummer R; Schadendorf D
    Arch Dermatol; 2008 May; 144(5):664-5. PubMed ID: 18490596
    [No Abstract]   [Full Text] [Related]  

  • 20. Adjuvant interferon therapy and rheumatoid arthritis--a contraindication?
    Tsianakas A; Schiller M; Luger TA; Sunderkoetter C
    Acta Oncol; 2009; 48(3):468-9. PubMed ID: 18759142
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.